Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 184
- Registration Number
- NCT00559637
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: EpidoxorubicinBiological: Bevacizumab
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT00559845
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 72
- Registration Number
- NCT00559754
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 106
- Registration Number
- NCT00559533
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 424
- Registration Number
- NCT00556322
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 889
- Registration Number
- NCT00556712
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
Phase 4
Completed
- Conditions
- Post-Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 781
- Registration Number
- NCT00551174
A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Chronic Renal Anemia
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT00550680
A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
Phase 2
Completed
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT00551291
A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT00546481
© Copyright 2025. All Rights Reserved by MedPath